The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Agenus; Celgene; Celldex; Endocyte; Macrogenics; Merck; Pharmacyclics
Research Funding - Merck
Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.
 
Luis A. Diaz
Leadership - Personal Genome Diagnostics
Stock and Other Ownership Interests - PapGene, Inc.; Personal Genome Diagnostics
Consulting or Advisory Role - Genentech; Merck; Personal Genome Diagnostics
Speakers' Bureau - Cell Design Labs
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - PapGene, PGDx and other entities have licensed several patent applications from Johns Hopkins, where Dr. Diaz is an inventor. These relationships are subject to certain restrictions under Johns Hopkins University policy, and the terms of these arrangement
Travel, Accommodations, Expenses - Merck
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Merck
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck
 
Takayuki Yoshino
Research Funding - Sumitomo Dainippon
 
Thierry Andre
Honoraria - Amgen; Baxter; BAYER; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Novartis; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche/Genentech
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Minori Koshiji
Employment - Merck
 
Yinghua Zhang
Employment - Merck
 
S. Peter Kang
No Relationships to Disclose
 
Bao Lam
Employment - Merck
 
Dirk Jaeger
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche